CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 8 | 10 | +2 |
| Shares | 24.6K | 124.3K | +99.6K (+404.8%) |
| Value | $221.5K | $652.4K | +$430.8K (+194.5%) |
New holders (4)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stonepine Capital Management, LLC | 48,827 | $256.3K | 0.20% |
| Ikarian Capital, LLC | 45,830 | $240.6K | 0.03% |
| Boothbay Fund Management, LLC | 13,524 | $71.0K | 0.00% |
| Sound Income Strategies, LLC | 16 | $113 | 0.00% |
Sold out (2)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Morgan Stanley | 28 | $252 |
| Citigroup Inc | 2 | $18 |